SharePoint
臺大醫院Logo
:::
:::
International Medical Service Center > Medical Services > Medical Services > Liver Disease Treatment

 Liver Diseases Treatment

 

Liver Disease Treatment Medical Team
        
    National
Taiwan University Hospital (NTUH) has played an important role in Taiwan regarding to the research and medical care of liver disease. In Taiwan, chronic hepatitis B and hepatitis C, and HBV- or HCV-related cirrhosis and hepatocellular carcinoma (HCC) are prevalent, and cause substantial morbidity and mortality in Taiwan. NTUH has devoted much effort to the HBV vaccination programme, screening and follow-up of patients with chronic hepatitis, treatment of both chronic hepatitis B and C, management of cirrhosis and its complications, and HCC therapy.

    By universal nationwide hepatitis B vaccination programme started in 1984, the prevalence rate of HBsAg carriage in children and teenagers dramatically declined in Taiwan. In addition to effective prevention of chronic HBV infection, anti-HBV treatments including standard interferon, long-acting pegylated interferon, nucleoside and nucleotide analogues are widely used to control chronic hepatitis B and its sequel. As to the treatment of chronic hepatitis C, combination therapy of pegylated interferon plus ribavirin is the current standard of care worldwide. Of particular note is that the concept of combination therapy for the treatment of chronic hepatitis C was originally invented and documented by the team in NTUH.  Several basic and clinical trials of novel agents for the treatment of various liver diseases are also ongoing in our benches and bedsides. 

    NTUH is also famous for her well-suited facilities and medical personnel, which provide patients complete medical care including screening, treatment and follow-up. Cirrhotic complications such as hepatic failure, hepatic encephalopathy, variceal bleeding, ascites, and HCC could be early detected and managed in advance. Liver transplantation in cooperation with transplant team for the management of end-stage liver disease is also available in NTUH.

    Adequate management of liver cancers, either primary or metastatic, remains a daunting challenge to a modern medical center. In addition to surgical resection and transarterial chemoembolization (TACE), novel local treatment modalities including microwave coagulation therapy and radiofrequency ablation have been introduced to treat liver cancers in recent years. Local ablation therapy is equally effective as surgical resection in the treatment of small HCC and has benefits of cheaper cost, shorter admission duration, and lower complication rates. Combination of different treatment modalities is also feasible for complicated patients. For advance HCC patients, molecular target therapy alone or in combination with other chemotherapeutic agents may be a choice in the future.

    In summary, NTUH owns well-equipped facilities and well-trained personnel that can provide high-standard and comprehensive service to liver disease patients from all over the world.

 
For International Medical Service (Self-pay) appointment,
Please contact us via phone at 886-2-2356-2900 or email to: ntuhimsc@ntuh.gov.tw 
 
 

(Last revised: 2017/05/08 by Joyce)